{"id":"https://openalex.org/W2301090715","doi":"https://doi.org/10.1517/14656566.2016.1162786","title":"Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions","display_name":"Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions","publication_year":2016,"publication_date":"2016-03-07","ids":{"openalex":"https://openalex.org/W2301090715","doi":"https://doi.org/10.1517/14656566.2016.1162786","mag":"2301090715","pmid":"https://pubmed.ncbi.nlm.nih.gov/26950414"},"language":"en","primary_location":{"id":"doi:10.1517/14656566.2016.1162786","doi":"https://doi.org/10.1517/14656566.2016.1162786","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.2016.1162786","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069757285","display_name":"Jody C. Chuang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210105015","display_name":"Stanford Health Care","ror":"https://ror.org/019wqcg20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210105015","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jody C. Chuang","raw_affiliation_strings":["a Division of Hematology and Oncology , Stanford Hospital & Clinics , Stanford , CA , USA","Division of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Division of Hematology and Oncology , Stanford Hospital & Clinics , Stanford , CA , USA","institution_ids":["https://openalex.org/I4210105015","https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"raw_affiliation_string":"Division of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA","institution_ids":["https://openalex.org/I4210105015","https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054698030","display_name":"Ameen Abdulla Salahudeen","orcid":"https://orcid.org/0000-0001-9037-3481","observed_orcids":["https://orcid.org/0000-0001-9037-3481"]},"institutions":[{"id":"https://openalex.org/I4210105015","display_name":"Stanford Health Care","ror":"https://ror.org/019wqcg20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210105015","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ameen A. Salahudeen","raw_affiliation_strings":["a Division of Hematology and Oncology , Stanford Hospital & Clinics , Stanford , CA , USA","Division of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Division of Hematology and Oncology , Stanford Hospital & Clinics , Stanford , CA , USA","institution_ids":["https://openalex.org/I4210105015","https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"raw_affiliation_string":"Division of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA","institution_ids":["https://openalex.org/I4210105015","https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035640724","display_name":"Heather A. Wakelee","orcid":"https://orcid.org/0000-0003-1136-980X","observed_orcids":["https://orcid.org/0000-0003-1136-980X"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Heather A. Wakelee","raw_affiliation_strings":["b Department of Medicine, Division of Oncology , Stanford University School of Medicine , Stanford , CA , USA","Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"b Department of Medicine, Division of Oncology , Stanford University School of Medicine , Stanford , CA , USA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"raw_affiliation_string":"Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5035640724"],"corresponding_institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"],"apc_list":null,"apc_paid":null,"fwci":2.6828,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.89864722,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":98},"biblio":{"volume":"17","issue":"7","first_page":"989","last_page":"993"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rociletinib","display_name":"rociletinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9679999947547913},{"id":"https://openalex.org/keywords/third-generation-egfr-tyrosine-kinase-inhibitors","display_name":"third-generation EGFR tyrosine kinase inhibitors","score":0.7480000257492065},{"id":"https://openalex.org/keywords/egfr-t790m-mutation","display_name":"T790M mutation","score":0.984000027179718},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.781000018119812},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.7350000143051147},{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":0.9100000262260437},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8169999718666077},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6489999890327454}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8364354968070984},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.540820837020874},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.4397073984146118},{"id":"https://openalex.org/C148043351","wikidata":"https://www.wikidata.org/wiki/Q4456944","display_name":"Current (fluid)","level":2,"score":0.42801952362060547},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4001677930355072},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35554540157318115},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.34851735830307007},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.19820764660835266},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1461200714111328},{"id":"https://openalex.org/C119599485","wikidata":"https://www.wikidata.org/wiki/Q43035","display_name":"Electrical engineering","level":1,"score":0.0},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/14656566.2016.1162786","doi":"https://doi.org/10.1517/14656566.2016.1162786","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.2016.1162786","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:26950414","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26950414","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1645759762","https://openalex.org/W1985264867","https://openalex.org/W1998971866","https://openalex.org/W2052705131","https://openalex.org/W2076178766","https://openalex.org/W2081384538","https://openalex.org/W2096198395","https://openalex.org/W2100506083","https://openalex.org/W2111662961","https://openalex.org/W2126177831","https://openalex.org/W2133963438","https://openalex.org/W2139236349","https://openalex.org/W2155894313","https://openalex.org/W2161821474","https://openalex.org/W2162724777","https://openalex.org/W2166084034","https://openalex.org/W2169460814","https://openalex.org/W2171139285","https://openalex.org/W2207941545","https://openalex.org/W2325170604","https://openalex.org/W2461360472","https://openalex.org/W2514615098","https://openalex.org/W2564720754"],"related_works":["https://openalex.org/W4301486820","https://openalex.org/W2048478480","https://openalex.org/W2559648825","https://openalex.org/W2307503596","https://openalex.org/W2741787483","https://openalex.org/W1526983978","https://openalex.org/W2892004169","https://openalex.org/W3083938891","https://openalex.org/W2502753163","https://openalex.org/W2528328390"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Major":[1],"advances":[2],"have":[3],"been":[4],"made":[5],"since":[6],"the":[7,18,34,37,49,81,96,104,113,118,124,133,141,174,194],"discovery":[8],"of":[9,20,36,52,80],"driver":[10,41],"mutations":[11,93],"and":[12,90,107,149,178,204],"their":[13,30],"targeted":[14,44],"therapies,":[15],"especially":[16],"in":[17,33,181],"treatment":[19,66],"patients":[21,38,191],"with":[22,39,67,86,117,167,200],"epidermal":[23],"growth":[24],"factor":[25],"receptor":[26],"(EGFR)":[27],"mutations.":[28],"Despite":[29],"initial":[31],"efficacy":[32],"majority":[35],"such":[40],"mutations,":[42],"all":[43],"therapies":[45],"are":[46,161],"limited":[47],"by":[48,173],"eventual":[50],"development":[51],"resistance":[53,63,143,206],"mechanisms.":[54],"AREAS":[55],"COVERED:":[56],"EGFR":[57,72,84,92,165],"T790M":[58,89,130,170],"mutation":[59,131],"is":[60,78,155],"a":[61,197],"common":[62],"mechanism":[64],"after":[65,145,208],"first":[68],"or":[69],"second":[70],"generation":[71,83,164],"tyrosine":[73],"kinase":[74],"inhibitors":[75],"(TKI).":[76],"Rociletinib":[77],"one":[79],"third":[82],"TKIs":[85,166],"activity":[87,168],"against":[88,169],"activating":[91],"while":[94],"sparing":[95],"wild-type":[97],"EGFR.":[98],"In":[99],"this":[100],"review,":[101],"we":[102,139],"discuss":[103],"current":[105],"understanding":[106],"available":[108],"data":[109],"on":[110,147,187],"rociletinib,":[111,148],"including":[112],"side":[114,202],"effects":[115],"associated":[116],"medication.":[119],"We":[120],"will":[121,185],"also":[122],"review":[123,140],"BEAMing":[125],"plasma":[126],"test":[127],"to":[128,157],"detect":[129],"without":[132],"need":[134],"for":[135],"repeat":[136],"biopsy.":[137],"Lastly,":[138],"potential":[142],"mechanisms":[144,207],"progression":[146],"future":[150],"directions.":[151],"EXPERT":[152],"OPINION:":[153],"It":[154],"important":[156],"note":[158],"that":[159],"there":[160],"other":[162],"3(rd)":[163],"already":[171],"approved":[172],"US":[175],"FDA":[176],"(osimertinib)":[177],"many":[179],"others":[180],"development.":[182],"Future":[183],"research":[184],"focus":[186],"figuring":[188],"out":[189],"which":[190],"can":[192],"benefit":[193],"most":[195],"from":[196],"particular":[198],"medication":[199],"minimal":[201],"effects,":[203],"further":[205],"rociletinib.":[209]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":6},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}